Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

BRACCO'S ACQUISITION OF SQUIBB DIAGNOSTICS creates a U.S. company with a broad diagnostic imaging agents pipeline, including contrast agents for x-ray, magnetic resonance imaging, and ultrasound, as well as radiopharmaceuticals. In addition to its core imaging products already on the market -- the x-ray imaging agent Isovue (iopamidol) and MRI contrast agent ProHance (gadoteridol) -- the Bristol-Myers Squibb subsidiary has at least three products in its pipeline.

You may also be interested in...

Bristol Gains Imaging Agent Pipeline Via DuPont Pharmaceuticals Acquisition

Bristol-Myers Squibb's acquisition of DuPont Pharmaceuticals includes an R&D pipeline of two imaging agents, one of which is pending at FDA, and a radiotherapeutic.

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts